On Wednesday, the Centers for Medicare & Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within CMS-approved studies.
This proposal follows Medtronic Plc’s (NYSE:MDT) request for a national coverage determination for renal denervation in December 2024. RDN is a procedure that reduces activity in the renal nerves, located in the kidneys, to help lower blood pressure.
